Navigation Links
SuperNova Diagnostics® to Present at AdvaMed 2011: The Medtech Conference in Washington, D.C.
Date:9/22/2011

GERMANTOWN, Md., Sept. 22, 2011 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, today announced that Neil J. Campbell, president and CEO, will be presenting at AdvaMed 2011: The Medtech Conference in Washington, D.C. on September 27, 2011 at 11:00 a.m. in room 204A of the Walter E. Washington Convention Center in Washington, D.C.  

The presentation will include an overview of SuperNova's proprietary point-of-care (POC) and point-of-use (POU) diagnostic technology targeting four industry sectors: human health, animal health, industrial and biodefense/biosecurity.

"AdvaMed 2011 is the premier event for investors and leaders in the medical technology industry, and thus is an ideal opportunity for SuperNova to showcase its game-changing, disruptive technology and 'lab-in-the-palm-of-your-hand' diagnostic system," said Mr. Campbell.  "With our proprietary AmpCrystal® platform, which provides an array of diagnostic capabilities from patient treatment to pathogen detection, SuperNova has the potential to seize the still largely untapped multi-billion dollar point-of-care and point-of-use diagnostic market."

About SuperNova Diagnostics®, Inc.

SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications.  A powerful proprietary nanochemistry, AmpCrystal®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements.  SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNova® — Putting the Laboratory in the Palm of Your Hand®.  For additional information, please visit www.supernovadiagnostics.com.

Contacts:
Tiberend Strategic Advisors, Inc.
Jason Rando / Madeleine Desmond
(212) 827-0020
jrando@tiberend.com / mdesmond@tiberend.com


'/>"/>
SOURCE SuperNova Diagnostics(R), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SuperNova Diagnostics® Announces Agreement with KSB Diagnostics of China to Commercialise Neopterin Diagnostics
2. SuperNova Diagnostics® Selected to Present at Launch: Silicon Valley 2011
3. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
4. InterMune to Present at Canaccord Adams Conference
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
8. Bionovo to Present at Canaccord Adams Global Growth Conference
9. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
10. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):